Milbank LLP has advised EQT Future, EQT’s new impact-driven longer-hold investment strategy, on an investment in SHL Medical AG. EQT Future, together with certain co-investors, will acquire its participation in SHL Medical AG from EQT VIII fund, which will exit the company. SHL Medical's founder, Roger Samuelsson, will remain the majority shareholder.
Having significantly outperformed its business plan since the investment by EQT VIII fund in January 2020, SHL Medical formulated an ambitious growth strategy until 2030, for which EQT Future and its co-investors will serve as partners.
SHL Medical designs, develops and manufactures advanced drug delivery devices, such as autoinjectors, pen injectors and advanced inhaler systems, and provides final assembly, labeling and packaging services for pharma and biotech companies worldwide. Headquartered in Switzerland with locations in Taiwan, Sweden, and the US, SHL Medical employs more than 5,000 employees worldwide.
The Milbank team, which advised EQT Future on corporate, tax and antitrust/FDI law aspects of the transaction, was led by partner Sebastian Heim (Corporate/M&A) and included partners Alexander Rinne (Antitrust/FDI) and Thomas Kleinheisterkamp (Tax), of counsel Jane L. Hanson (Litigation & Arbitration), special counsel James Beebe (Employment) as well as associates Pascal Härdtner, Mahmood Kawany, Bernd Galneder (all Corporate/M&A), Stefanie Gschoßmann (Antitrust), Javier J. Ramos (Litigation & Arbitration), Benjamin Kamelhar (Real Estate) and Jon Sorger (Employment).
